title: Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
abstract: BACKGROUND
  Erlotinib therapy for non small-cell lung cancer (NSCLC) has mainly been evaluated in randomized trials.
  
  
  METHODS
  OBSTAR was a multicenter, retrospective, observational study involving all patients treated with erlotinib in 18 French centers between June 2005 and September 2007. The analyses focused on the patients' characteristics, previous treatments, and treatment efficacy during a three-year follow-up period.
  
  
  RESULTS
  534 patients were included in this study. The median survival times were respectively 5.2 [3.7-7.4] and 4.7 [4.1-5.7] months, depending to whether erlotinib was used as second- (n=190), or ≥ third-line treatment (n=305). The disease control rate were 39.1% [30.2-48.7] and 29.9% [29.6-36.9] according to the line of treatment. Factors predictive of an objective response were gender, age, and smoking status. Factors predictive of progression were age, sex, smoking status, the line of treatment, and the number of metastases. Treatment had to be interrupted for toxicity in 8.5% of cases.
  
  
  CONCLUSIONS
  This study of erlotinib therapy in 2005-2007 confirms, in the general NSCLC patient population, the results of pivotal trials.
authors.affiliation: Service de Pneumologie, Hôpital du Cluzeau, et Unité de Recherche Clinique et Biostatistique, CHU - Limoges, France. alain.vergnenegre@unilim.fr
authors.forename: A
authors.initials: A
authors.lastname: Vergnenègre
authors.forename: I
authors.initials: I
authors.lastname: Monnet
authors.forename: C
authors.initials: C
authors.lastname: Chouaïd
authors.forename: J
authors.initials: J
authors.lastname: Hureaux
authors.forename: J
authors.initials: J
authors.lastname: Mazières
authors.forename: G
authors.initials: G
authors.lastname: Quéré
authors.forename: J N
authors.initials: JN
authors.lastname: Lombard
authors.forename: I
authors.initials: I
authors.lastname: Cumin
authors.forename: S
authors.initials: S
authors.lastname: Abdiche
authors.forename: C Nocent
authors.initials: CN
authors.lastname: Ejnaini
authors.forename: H
authors.initials: H
authors.lastname: Bonnabau
authors.forename: Ch
authors.initials: Ch
authors.lastname: Decroisette
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D018572:Disease-Free Survival; D000069347:Erlotinib Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking; D016019:Survival Analysis; D028761:Withholding Treatment
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride